{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:08:13Z","timestamp":1787508493826,"version":"build-2736575974"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Phosphate retention and, later, hyperphosphatemia are key contributors to chronic kidney disease (CKD)\u2013mineral and bone disorder (MBD). Phosphate homeostatic mechanisms maintain normal phosphorus levels until late-stage CKD, because of early increases in parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23). Increased serum phosphorus, and these other mineral abnormalities, individually and collectively contribute to bone disease, vascular calcification, and cardiovascular disease. Earlier phosphate control may, therefore, help reduce the early clinical consequences of CKD-MBD, and help control hyperphosphatemia and secondary hyperparathyroidism in late-stage CKD. Indeed, it is now widely accepted that achieving normal phosphorus levels is associated with distinct clinical benefits. This therapeutic goal is achievable in CKD stages 3 to 5 but more difficult in dialysis patients. Currently, phosphate control is only initiated when hyperphosphatemia occurs, but a potentially beneficial and simple approach may be to intervene earlier, for example, when tubular phosphate reabsorption is substantially diminished. Early CKD-MBD management includes dietary phosphate restriction, phosphate binder therapy, and vitamin D supplementation. Directly treating phosphorus may be the most beneficial approach because this can reduce serum phosphorus, PTH, and FGF-23. This involves dietary measures, but these are not always sufficient, and it can be more effective to also consider phosphate binder use. Vitamin D sterols can improve vitamin D deficiency and PTH levels but may worsen phosphate retention and increase FGF-23 levels, and thus, may also require concomitant phosphate binder therapy. This article discusses when and how to optimize phosphate control to provide the best clinical outcomes in CKD-MBD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.05130610","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T22:23:14Z","timestamp":1296771794000},"page":"440-446","source":"Crossref","is-referenced-by-count":100,"title":["Prevention and Control of Phosphate Retention\/Hyperphosphatemia in CKD-MBD"],"prefix":"10.2215","volume":"6","author":[{"given":"Kevin J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230811","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1755-6686.2009.00050.x","article-title":"Pathogenesis of bone and mineral related disorders in chronic kidney disease: Key role of hyperphosphatemia","volume":"35","author":"Roman-Garcia","year":"2009","journal-title":"J Ren Care"},{"key":"R2-28-20230811","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/039139880903200203","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"32","author":"Cozzolino","year":"2009","journal-title":"Int J Artif Organs"},{"key":"R3-28-20230811","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0b013e328331a8c8","article-title":"Fibroblast growth factor 23 and the future of phosphorus management","volume":"18","author":"Wolf","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R4-28-20230811","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest"},{"key":"R5-28-20230811","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","article-title":"Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells","volume":"195","author":"Krajisnik","year":"2007","journal-title":"J Endocrinol"},{"key":"R6-28-20230811","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ki.2010.260","article-title":"Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients","volume":"78","author":"Krajisnik","year":"2010","journal-title":"Kidney Int"},{"key":"R7-28-20230811","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1006\/bbrc.2000.4226","article-title":"Severely reduced production of klotho in human chronic renal failure kidney","volume":"280","author":"Koh","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"R8-28-20230811","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R9-28-20230811","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1053\/j.ajkd.2007.12.018","article-title":"Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999\u20132004","volume":"51","author":"Vassalotti","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R10-28-20230811","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R11-28-20230811","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"R12-28-20230811","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-07-0534","article-title":"Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men","volume":"158","author":"Marsell","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R13-28-20230811","doi-asserted-by":"crossref","first-page":"V2","DOI":"10.1093\/ndt\/gfh1049","article-title":"The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes","volume":"19","author":"Horl","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R14-28-20230811","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/gfn620","article-title":"Does FGF23 toxicity influence the outcome of chronic kidney disease?","volume":"24","author":"Razzaque","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R15-28-20230811","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R16-28-20230811","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R17-28-20230811","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R18-28-20230811","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1053\/j.ajkd.2008.07.036","article-title":"Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III)","volume":"53","author":"de Boer","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R19-28-20230811","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch Intern Med"},{"key":"R20-28-20230811","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ahj.2008.05.016","article-title":"Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"156","author":"Foley","year":"2008","journal-title":"Am Heart J"},{"key":"R21-28-20230811","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04100808","article-title":"Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA","volume":"4","author":"Ix","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R22-28-20230811","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"R23-28-20230811","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1053\/j.ajkd.2005.08.013","article-title":"The Kidney Disease Outcomes Quality Initiative (K\/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients","volume":"46","author":"Noordzij","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R24-28-20230811","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R25-28-20230811","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R26-28-20230811","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/ajkd.2001.24533","article-title":"Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells","volume":"37","author":"Ahmed","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R27-28-20230811","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R28-28-20230811","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"R29-28-20230811","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R30-28-20230811","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"R31-28-20230811","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"R32-28-20230811","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.mad.2010.02.008","article-title":"A potential link between phosphate and aging: Lessons from Klotho-deficient mice","volume":"131","author":"Kuro-o","year":"2010","journal-title":"Mech Ageing Dev"},{"key":"R35-28-20230811","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1172\/JCI108781","article-title":"Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog","volume":"60","author":"Rutherford","year":"1977","journal-title":"J Clin Invest"},{"key":"R36-28-20230811","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.2009.246","article-title":"A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease","volume":"76","author":"Isakova","year":"2009","journal-title":"Kidney Int"},{"key":"R37-28-20230811","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00467-007-0508-0","article-title":"Parathyroid hormone assay: Problems and opportunities","volume":"22","author":"Martin","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R38-28-20230811","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/000456329803500203","article-title":"Renal tubular reabsorption of phosphate (TmP\/GFR): Indications and interpretation","volume":"35","author":"Payne","year":"1998","journal-title":"Ann Clin Biochem"},{"key":"R39-28-20230811","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000045015","article-title":"Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation","volume":"79","author":"Barsotti","year":"1998","journal-title":"Nephron"},{"key":"R40-28-20230811","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ki.1994.408","article-title":"Phosphorus and protein restriction and parathyroid function in chronic renal failure","volume":"46","author":"Combe","year":"1994","journal-title":"Kidney Int"},{"key":"R41-28-20230811","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000188606","article-title":"Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol)","volume":"70","author":"Combe","year":"1995","journal-title":"Nephron"},{"key":"R42-28-20230811","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure","volume":"29","author":"Martinez","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R43-28-20230811","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000045021","article-title":"Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients","volume":"79","author":"Soroka","year":"1998","journal-title":"Nephron"},{"key":"R44-28-20230811","first-page":"837","article-title":"Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: A prospective, randomized, controlled trial","volume":"81","author":"Williams","year":"1991","journal-title":"Q J Med"},{"key":"R45-28-20230811","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney Int"},{"key":"R46-28-20230811","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ki.1992.407","article-title":"Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy","volume":"42","author":"Lafage","year":"1992","journal-title":"Kidney Int"},{"key":"R47-28-20230811","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1210\/jcem.84.2.5485","article-title":"Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction","volume":"84","author":"Lafage-Proust","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-28-20230811","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"R49-28-20230811","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.ajkd.2009.01.269","article-title":"Dietary phosphorus restriction in dialysis patients: Potential impact of processed meat, poultry, and fish products as protein sources","volume":"54","author":"Sherman","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R50-28-20230811","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.2215\/CJN.02830409","article-title":"Phosphorus and potassium content of enhanced meat and poultry products: Implications for patients who receive dialysis","volume":"4","author":"Sherman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R51-28-20230811","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2009.96","article-title":"Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial","volume":"301","author":"Sullivan","year":"2009","journal-title":"JAMA"},{"key":"R52-28-20230811","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.2008060609","article-title":"Phosphorus binders and survival on hemodialysis","volume":"20","author":"Isakova","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R53-28-20230811","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R54-28-20230811","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"R55-28-20230811","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"R56-28-20230811","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification: Results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"R57-28-20230811","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R58-28-20230811","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"R59-28-20230811","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R60-28-20230811","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2215\/CJN.06140809","article-title":"Calcium in chronic kidney disease: Myths and realities","volume":"5","author":"Langman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R61-28-20230811","first-page":"CD008175","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R62-28-20230811","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R63-28-20230811","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"key":"R64-28-20230811","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R65-28-20230811","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1525-139X.2009.00566.x","article-title":"When is vitamin D contraindicated in dialysis patients?","volume":"22","author":"Martin","year":"2009","journal-title":"Semin Dial"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:27Z","timestamp":1786369227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00028"}},"subtitle":["What Is Normal, When to Start, and How to Treat?"],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.05130610","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}